STELLA PHARMA CORPORATION (Head office: Chuoku, Osaka City; President: Tomoyuki Asano) is pleased to announce that Steboronine® intravenous drip bag 9000 mg/300 mL (Generic name: Borofalan [10B]; “Steboronine®”), a boron drug for boron neutron capture therapy (“BNCT”), has been listed on the National Health Insurance Drug Price List, as published in the Official Gazette today (May 19,2020). We are also pleased to announce that the product will be available for sale on May 20.
STELLA PHARMA will launch Steboronine®, the World’s First BNCT Drug, on May 20, 2020
